Teva Claws Its Way Back With Earnings, Revenue Beat

  • Teva Claws Its Way Back With Earnings, Revenue Beat

Teva Claws Its Way Back With Earnings, Revenue Beat

The stock has a 1-year performance down -38.78% and a negative weekly performance at -6.53%. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/02/14/teva-pharmaceutical-industries-limited-teva-price-target-lowered-to-33-00-at-jefferies-group-llc.html. Pillar Pacific Capital Management LLC now owns 79,069 shares of the company's stock worth $3,972,000 after buying an additional 3,873 shares in the last quarter. Washington Trust Bank boosted its position in shares of Teva Pharmaceutical Industries Limited by 2.7% in the third quarter. Washington Trust Bank now owns 2,232 shares of the company's stock worth $103,000 after buying an additional 58 shares during the period. Pillar Pacific Capital Management LLC increased its position in shares of Teva Pharmaceutical Industries Limited by 5.2% in the second quarter. The institutional investor owned 126,484 shares of the company's stock after buying an additional 6,100 shares during the period. The company reported $1.31 EPS for the quarter, beating the analyst consensus estimate by $ 0.03.

"This is a critical time for Teva, and we are here to fix what is not working", he added during the company's call with investors Monday. (NYSE:BKD) shares moved to $15.15 after opening the day at $15.41, on Friday. 10,387,741 shares of the company's stock traded hands. The company's price sits -8.83% below from its 50-day moving average of $34.65 and -29.12% away from the stock's 200-day moving average which is $43.09. The firm has a market cap of $33.92 billion, a price-to-earnings ratio of 19.4380 and a beta of 0.58.

At the movement Teva Pharmaceutical Industries Limited (NYSE:TEVA) is under coverage by number of analysts. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)'s price to sales ratio for trailing twelve month stands at 1.59, whereas its price to book ratio for most recent quarter sits at 1.00.

Teva is expected to report earnings of $1.32/share on $6.26 billion in revenue.

In its outlook statement, Teva said it expects full-year revenues of $23.8 billion to $24.5 billion for the 2017 fiscal year and non-GAAP EPS in the range of $4.90 to $5.30. During the same quarter in the prior year, the firm posted $1.32 earnings per share. This was up from $1.14 billion, or $1.28 per share, in last year's fourth quarter.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) now has a consensus Price Target of $42.09.

Several research firms recently weighed in on TEVA. Citigroup Inc. reissued a buy rating and set a $47.00 price target on shares of Teva Pharmaceutical Industries Limited in a research report on Tuesday, February 7th. Immediately after the results were published, Teva's share price rose 4.3%. Mizuho lowered their price objective on shares of Teva Pharmaceutical Industries Limited from $45.00 to $40.00 and set a "neutral" rating on the stock in a research report on Wednesday, November 16th. The company is set at a mean analysts' recommendation of 2.20. The company has an average rating of "Buy" and a consensus price target of $53.88.

To the market's relief, the company, Israel's biggest, also affirmed its projections for sales and earnings, even though acting CEO Yitzhak Peterburg estimated that the impact from new generic competition to its best-selling Copaxone drug would be somewhat more serious than previously forecast.

Among analysts and investors, a widespread belief is that Teva could split in two-one side, the company's generics business, the other, its branded drug company.